Emergo Therapeutics, Inc.

DURHAM, NC · Founded 2016 · CIK 0001741198 · Biotech · Private

Immunomodulatory therapeutics for immune-mediated diseases

emergotherapeutics.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$4.0M
3 Form D · May 2022
53 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$12,000,000
Private capital raisedForm D · SEC$3,524,137
Private capital raisedForm D · SEC$500,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1719Peroxitech LLC——
1720SAMBA BIOLOGICS INC.——
1721AAVOGEN INC——
1722Emergo Therapeutics, Inc.—$4.0M
1723Sensible Biotechnologies, Inc.—$15M
1724Pulmocide——
1725Jaguar Gene Therapy——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • John Bailey, Jr.Director
  • John E. Bailey, Jr.Director
  • Robert HelmedagDirector
  • Robin Hyde-DeRuyscherDirector · Executive Officer
  • Moise KhayrallahDirector · Executive Officer
  • Margaret PowellDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.